All In Biotech

Drug Trial Radar · NCT07514338

Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of KL1333 (Napazimone) in Patients With Primary Mitochondrial Disease

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Mar 31, 2029

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Pharming Technologies B.V.Industry
Sponsor type
Industry
Collaborators
ICON plc
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate if the study medicine, KL1333, is safe, well-tolerated and effective long-term in improving the symptoms of fatigue and impacts on daily living and functional capacity (physical abilities) in people with PMD.

Conditions

  • Mitochondrial Diseases

Interventions

  • NapazimoneDrug

    Product: KL1333 (international nonproprietary name: napazimone) Dose: Each subject will be up-titrated to his/her maximum well tolerated dose. The starting dose will be 25 mg KL1333 twice daily (BID; total daily dose of 50 mg). If KL1333 is considered to be well tolerated after 4 weeks of treatment, the dose will be increased to 50 mg KL1333 BID (total daily dose of 100 mg). The dose may be lowered from 50 mg BID to 25 mg BID at the investigator's discretion throughout the study in case of tolerability issues. Frequency: Twice daily Route: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Through study at least for 48 weeks
  2. Physical examinationTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
  3. Vital signsTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
  4. ElectrocardiogramTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
  5. Safety laboratory - blood chemistryTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
  6. Safety laboratory - urinalysisTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
  7. Safety laboratory - hematologyTime frame: At Baseline Week 0, Week 4, Week 24 and Week 48
  8. Occurence of metabolic decompensation and lactic acidosis or image-verified stroke-like episodes consequent to GI AE and AESIsTime frame: Through study at least for 48 weeks
  9. Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: At Baseline Week 0

Locations

23 sites in 9 countries. Site status is shown where the registry gives one.

  • Akron Children's Hospital

    Akron, Ohio · Recruiting

  • Hospital Erasme

    Brussels, Belgium · Recruiting

  • Hopital Universitaire de Bruxelles (H.U.B)/ Academisch Ziekenhuis Brussel

    Brussels, Belgium · Recruiting

  • University Hospital

    Ghent, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • University Hospital

    Leuven, Belgium · Recruiting

  • Universitair Ziekenhuis Leuven Gasthuisberg Campus

    Leuven, Belgium · Recruiting

  • Charles University and General University Hospital

    Prague, Czechia · Recruiting

  • Copenhagen Neuromuscular Center, Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Centre Hospitalier Universitaire d'Angers

    Angers, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin

    Bordeaux, France · Recruiting

  • Hopital Roger Salengro, CHRU de Lille

    Lille, France · Recruiting

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France · Recruiting

  • Centre Hospitalier Universitaire de Nice, Hopital Pasteur 2

    Nice, France · Recruiting

  • CHU de NICE - Hôpital Archet 2

    Nice, France · Recruiting

  • Hopitaux Universitaires de Strasbourg

    Strasbourg, France · Recruiting

  • Universitaetsklinikum Halle

    Halle, Germany · Recruiting

  • Azienda Ospedaliera Universitaria Gaetano Martino Messina

    Messina, Italy · Recruiting

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy · Recruiting

  • Radboud University Medical Center

    Nijmegen, Netherlands · Recruiting

  • Hospital General Universitario de Catalunya

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.